Analysts Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) PT at $18.00

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.00.

EPRX has been the topic of several recent research reports. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EPRX. Persistent Asset Partners Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals during the second quarter worth $25,000. BlackRock Inc. acquired a new position in Eupraxia Pharmaceuticals in the second quarter valued at $40,000. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at $76,000. Guardian Wealth Advisors LLC NC bought a new stake in Eupraxia Pharmaceuticals during the fourth quarter valued at $76,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Eupraxia Pharmaceuticals during the third quarter valued at $71,000.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ:EPRX opened at $6.77 on Monday. The firm has a market cap of $440.19 million, a PE ratio of -6.45 and a beta of 1.08. The firm’s fifty day moving average is $6.41 and its 200-day moving average is $7.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. Eupraxia Pharmaceuticals has a 52 week low of $5.04 and a 52 week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.